|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 409 12th Street, SW |
Address2 |
|
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
|
5. Senate ID# 400578740-12
|
||||||||
|
6. House ID# 412490000
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kira Peterson |
Date | 7/20/2026 3:05:09 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Womens health research (general); Centers for Disease Control and Prevention (CDC); CDC Office on Smoking and Health; National Institutes of Health (NIH); NIH workforce training programs; National Center for Health Statistics; Division of Sexually Transmitted Disease Prevention; Agency for Healthcare Research and Quality (AHRQ); NIH Office of Research on Womens Health; Health Resources and Services Administration (HRSA); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Safe Motherhood and Infant Health Program (CDC); IHS funding (general); National Center for Chronic Disease Prevention and Health Promotion (CDC); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC); inclusion of pregnant and lactating people in clinical trials (general); Congressionally Directed Medical Research Program (CDMRP); Title X family planning program; Title V Maternal and Child Health Block Grant; Title VII Health Professions and Title VIII Nursing Workforce Development programs; Pregnancy Risk Assessment Monitoring System (CDC); Teaching Health Center Graduate Medical Education Program (THCGME); Healthy Start; National Maternal Mental Health Hotline; maternal mental health programs; Alliance for Innovation on Maternal Health (AIM); stillbirth prevention; Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET); firearm injury and prevention research; menopause education; Womens Reproductive Health Research (WRHR); National Center for Environmental Health; Center for Substance Abuse Treatment Pregnant and Postpartum Womens Residential Services Grant Program; State Pilot Program for Treatment for Pregnant and Postpartum Women (PPW-PLT); SPRANS; Teen Pregnancy Prevention Program; CDC newborn screening; ovarian cancer detection (general); NIH ECHO Program; Neglected Surgical Conditions; Pediatric Specialty Loan Repayment Program; Agency for Toxic Substances and Disease Registry; WIC; OMB Rule of Federal Financial Assistance.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Sarah |
Bogdan |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
FY27 National Defense Authorization Act; IVF coverage for servicemembers and dependents (general)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Sarah |
Bogdan |
|
|
|
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Abortion access (general); Access to mifepristone (general); Contraception (general); Maternal mortality and morbidity (general); H.R. 8651/S. _____, Advancing Safe Medications for Moms and Babies Act; Obstetric and gynecologic care in rural and underserved areas (general); impact of closures of labor and delivery units in rural hospitals on patient access to care and maternal morbidity and mortality; abortion training in obstetrics and gynecology residency programs (general); Teaching Health Center Graduate Medication Education program (general); implementation of P.L. 119-21, One Big, Beautiful Bill Act; implementation of Sec. 6501 of P.L. 119-75, Preventing Maternal Deaths Reauthorization Act; Telemedicine (general); S. 380/H.R. 1254, Rural Obstetrics Readiness Act; S. 1834/H.R. 3762, Supporting Healthy Moms and Babies Act; H.R. 7973, Momnibus Act; H.R. 7830, WELLS Act; H.R.8159, Gynecologic Pain Management Study Act; H.R.8160, Premenstrual Dysphoric Disorder Awareness and Research Act; H.R. 9441, SAFE Training for OBGYNs Act; H.R. 9061, PREEMPT Act; H.Res. 1282, a resolution recognizing ACOGs 75th anniversary; H.R. 8358, Breast Cancer Research Stamp Reauthorization Act; S. Res. 710, a resolution recognizing Maternal Mental Health Day; H.R. 9090/S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act; H.Res. 1323, a resolution recognizing National Menstrual Health Awareness Month; H.R. 8500, Timely Access to Coverage Decisions Act; H.R. 7694, Gwenns Law; S. 4878, Reproductive Health Care Training Act; H.R. _____/S. _____, Right to IVF Act; S. 4494, America Cures Act; maternal mortality review committees (general); Patient-physician relationship (general); Obstetrician-gynecologist workforce (general); Substance use disorder during pregnancy (general); Maternal mental health (general); Insurance coverage for infertility (general); Protections for in vitro fertilization (general); Vaccination (general); childhood vaccine recommendations (general); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) recommendations (general); inclusion of pregnant and lactating women in clinical trials (general); pregnancy exposure registries (general); NIH/NICHD womens health research (general); access to fertility services and treatments (general); Restorative Reproductive Medicine (general); Advisory Committee on Immunization Practices (ACIP); COVID vaccine during pregnancy (general); S. 4550/H.R. 8807, Maternal Health Pandemic Response Act; United States Preventive Services Taskforce (general); hormone therapy for menopause symptoms (general); acetaminophen use during pregnancy (general); SSRI use during pregnancy (general); Pregnancy Risk Assessment Monitoring System (PRAMS); Maternal Mortality Review Information Application (MMRIA); FACE Act implementation; Nexplanon REMS; chaperones during sensitive procedures (general); FDA regulation of flavored e-cigarettes (general); ORR policies regarding pregnant minors (general); breast cancer risk assessment (general).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Sarah |
Bogdan |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
Treatment of pregnant and postpartum people in immigration detention (general); access to medical care in immigration detention (general); H.R. 1061/S. 455, Protecting Sensitive Locations Act; H-1B and J-1 visa delays/disruptions for physicians and trainees (general); H.R. 7961, H-1Bs for Physicians and the Healthcare Workforce Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Sarah |
Bogdan |
|
|
|
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Physician payment under Medicare (general); Medicare Physician Fee Schedule Efficiency Adjustment (general); Graduate medical education (general); S.1816/H.R. 3514, Improving Seniors Timely Access to Care Act of 2025; Prior authorization in Medicare (general); Medicaid (general); Physician payment under Medicaid (general); Medicaid work requirements (general); CMS billing and coding procedures (general); preserving postpartum Medicaid extension (general); implementation of P.L. 119-21, One Big, Beautiful Bill Act; telehealth (general); H.R. 7520, Efficiency Adjustment Delay Act; H.R. 8163, Provider Reimbursement Stability Act; FMAP for Puerto Rico; unbundling of obstetric codes in Medicare
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Sarah |
Bogdan |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
|
Lisa |
Satterfield |
|
|
|
Taylor |
Platt |
|
|
|
Erin |
Alston |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOR
16. Specific lobbying issues
H.R. 8582/S. 4436, Protecting Human Rights and Public Health in Foreign Assistance Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Abortion access at the VA (general); H.R. 7841, Warrior Infertility Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sarah |
Bogdan |
|
|
|
Rebecca |
Lauer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |